BRISBANE, Australia – The first patients have been enrolled in a chronic heart failure trial using Impedimed’s SOZO device at Scripps Health. “The trial, together with other clinical trials, will form the foundation of our marketing of SOZO,” said Richard Carreon, managing director and CEO of ImpediMed, in a statement. The SOZO device is used to measure, monitor and manage fluid status and body composition, and may provide an early warning system for cardiac patients. The trial will monitor up to 30 patients in a clinical setting for 30 days. The data generated from the study will form the basis for the design of a larger scale trial later this year.
You are here: / / Impedimed’s SOZO being used in Scripps cardiac trial